News | January 04, 2026
Elanco scores USDA nod for new canine allergy drug Befrena
Elanco expects Befrena to launch in the US in the first half of 2026
Elanco expects Befrena to launch in the US in the first half of 2026
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The plant is expected to enhance regional supply capabilities
Subscribe To Our Newsletter & Stay Updated
